Press Releases
Looking for more press releases? Explore our full press release archive by date to access past announcements, news updates, and media releases published on Technology News Journal.

Language Scientific Research Study Shows AI Integration Cuts Multimedia Localization Costs by Over 80%
Language Scientific to present findings at MT Summit 2025 in Geneva highlighting productivity gains without compromising quality. BOSTON, MA, UNITED STATES, June 16, 2025 /EINPresswire.com/ -- Language Scientific is pleased to announce that its...

Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer
MORRISTOWN, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTC:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex...

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology
Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanoma Fosun Pharma-Teva collaboration agreement established with goal of accelerating clinical data generation...

Bayer Innovation Procurement Expands Use of Scientist.com’s AI-Powered Platform for Global R&D Procurement Orchestration
Bayer AG Innovation Procurement and Scientist.com have signed a multi-year extension that elevates Scientist.com to Bayer’s preferred global channel for sourcing external R&D services. A Journey from Tactical to Strategic Partnership The alliance...

Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year
BOSTON and LONDON, June 16, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND to initiate a Phase 1...

BlueGenes and Levrx Partner to Integrate Real-Time Genetic Insights into the Pharmacy Benefit Experience
SCOTTSDALE, Ariz., June 16, 2025 (GLOBE NEWSWIRE) -- BlueGenes, a leading pharmacogenetics (PGX) solution, and Levrx Technology, a digital pharmacy engagement platform, have announced a strategic partnership. Together they aim to accelerate the...

Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025
SAN DIEGO, June 16, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that it will host an in-person and virtual R&D Day in New York on Thursday, June 26, 2025, from 9:00 AM to 12:00 PM ET. The event will...

Milestone Pharmaceuticals Submits Response to the FDA’s CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting
MONTREAL and CHARLOTTE, N.C., June 16, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced submission of its response to the U.S. Food and Drug Administration (FDA)’s Complete Response Letter (CRL) regarding its...

RFMW and Sonoma Scientific Announce Distribution Agreement to Deliver High-Performance Ferrite Isolators and Circulators
RFMW, a premier distributor of RF, microwave, and power components, is pleased to announce a new distribution agreement with Sonoma Scientific, a U.S.-based manufacturer specializing in high-quality ferrite isolators and circulators. Sonoma...

Inquis Medical’s AVENTUS Thrombectomy System Receives FDA 510(k) Clearance for Treatment of Pulmonary Embolism
MENLO PARK, Calif., June 16, 2025 (GLOBE NEWSWIRE) -- Inquis Medical, the leading innovator in the treatment of venous thromboembolic disease, today announced that its AVENTUS Thrombectomy System has received 510(k) clearance from the U.S. Food...

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032
FLORHAM PARK, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that the...

Tufts Center Study Shows Significant Time Savings in Delivering Therapies to Patients with Thermo Fisher Scientific’s Accelerator™ Drug Development 360° CDMO and CRO Solutions
Thermo Fisher Scientific Inc., the world leader in serving science, today announced the findings of new research by the Tufts Center for the Study of Drug Development (CSDD) demonstrating the benefits of the company’s Accelerator™ Drug Development...

Korea Smart Healthcare Association and SL Foundation Sign MOU for Development of Multimodal, AI, and Blockchain-Based Medical Platform
Singapore, June 16, 2025 (GLOBE NEWSWIRE) -- On June 10, 2025, the Korea Smart Healthcare Association (Chairman: Ki-Jun Shim) and SL Foundation (CEO: Sang-Sub Gong) signed a Memorandum of Understanding (MOU) to form a strategic partnership aimed...

Syncromune® Appoints Industry Veteran Kerri-Ann Millar as Chief Financial Officer to Advance Corporate Growth Initiatives and Clinical Development Program
FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, June 16, 2025 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage biopharmaceutical company pioneering SYNC-T, an in situ personalized combination immunotherapy platform for solid tumor cancers,...

ODYSIGHT.AI is strengthening its European Presence to Accelerate Industry 4.0: received Initial Order from Leading EU Player for AI-Driven industrial predictive health monitoring solutions"
OMER, Israel, June 16, 2025 (GLOBE NEWSWIRE) -- Odysight.AI Inc. (Nasdaq: ODYS), a pioneering developer of AI systems for Predictive Maintenance (PdM) and Condition-Based Monitoring (CBM), is pleased to announce the receipt of an initial order for...

Lung Cancer Patient in Lantern Pharma’s Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, today announces remarkable clinical observations for a patient in Lantern’s Phase 2 HARMONIC™...

MUSC receives historic $50 million anonymous gift to transform health care, medical education in South Carolina
Charleston, SC, June 16, 2025 (GLOBE NEWSWIRE) -- The Medical University of South Carolina (MUSC) College of Medicine has received a landmark $50 million anonymous donation—the largest single gift in MUSC’s 200-year history. This transformational...

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)
Poster #1654 highlights clinically meaningful and durable increases in circulating neutrophils observed with mavorixafor treatment +/- G-CSF over 6-month study Poster #1669 highlights findings that investigators were willing and able to reduce...

PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based AS9100D & ISO 9001:2015 Certified CNC Machine Shop Serving Aerospace, Defense, and Industrial Markets for over 35 years
Acquisition Target Specializes in Precision Milling, Turning, Mold Manufacturing, and Specialty Metals Expertise Serving Aerospace, Defense, and Industrial Markets This is PMGC’s third pending acquisition since April of 2025, demonstrating that...

Actelis Networks Accelerates US Federal Government and Military Expansion Efforts, Hires Industry Veteran Sales Director as Company accelerates efforts in Major Military Branches
FREMONT, Calif, June 16, 2025 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ: ASNS) ("Actelis" or the "Company"), a market leader in cyber-hardened, rapid deployment networking solutions for IoT and broadband applications, today announced that...